ResMed (RMD) is back in focus after CEO Michael Farrell sold about US$1.25 million of stock under a pre arranged trading plan. This move coincided with a 2% share decline.
See our latest analysis for ResMed.
Beyond the CEO sale and today’s 2% move, ResMed’s share price has been under pressure in recent weeks, with a 7 day share price return of 8.82% and a 30 day share price return of 8.69%, while the 1 year total shareholder return of 3.53% points to softer recent momentum compared with the longer term 5 year total shareholder return of 26.86%.
If you are reassessing healthcare exposure after this volatility, it could be a good time to look at other respiratory and treatment related names through a broader healthcare AI theme using the Simply Wall St screener for 33 healthcare AI stocks
With ResMed now trading below some analyst targets and recent returns lagging its longer term track record, the key question for you is whether current prices reflect temporary worries or whether the market is already factoring in future growth.
Most Popular Narrative: 22.3% Undervalued
ResMed's most followed narrative implies a fair value of $296.87 versus the last close of $230.61, putting a spotlight on the gap that narrative followers are watching closely.
Strategic investments in expanding the diagnosis and treatment funnel, including acquisitions like VirtuOx, Ectosense, and Somnoware, are improving patient flow from screening to therapy, positioning ResMed to capture a larger share of the substantial underpenetrated global sleep apnea and respiratory market, supporting long term revenue growth.
Curious what sits behind that upside case? The narrative leans on steadily rising revenue, firm profit margins and a future earnings multiple that still assumes discipline, not perfection.
Result: Fair Value of $296.87 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this upside story can quickly look different if US reimbursement tightens or if alternative therapies such as GLP 1 drugs and nerve stimulators gain share faster than expected.
Find out about the key risks to this ResMed narrative.
Next Steps
With sentiment in this article leaning toward cautious optimism, now is the time to review the numbers yourself and compare that view with your own expectations. To understand what the market currently sees as the upside drivers, take a closer look at the 5 key rewards
Looking for more investment ideas?
If ResMed has sharpened your thinking, do not stop here. Broaden your watchlist now so you are not chasing opportunities after everyone else moves.
- Target income resilience by scanning companies with reliable payouts using the 15 dividend fortresses.
- Hunt for quality businesses trading below their implied worth through the 47 high quality undervalued stocks.
- Prioritise capital preservation by focusing on companies highlighted in the 74 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com